Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma

Isavuconazole to begin at least 3 days prior to ibrutinib and continue throughout chemotherapy (cycles 1-6)

Temozolomide, etoposide, doxil, dexamthasone, ibrutinib (TEDDI) given every 21 days for cycles 2-6 (Arm 1-A); given every 21 days for cycles 1-6 (Arms 1-B, 2, 3 and 4)

Rituximab (R) given with TEDD and TEDDI every 3 weeks for cycles 1-6 (all arms)

Cytarabine given via Ommaya reservoir (IT therapy) on days 1 and day 5 of cycles 2-6 (all arms)

Temozolomide, etoposide, doxil, dexamthasone, (TEDD) given on first cycle (Arm 1-A)

Ibrutinib given on day -3 to day -1 on cycle 1 (Arms 2, 3 and 4)

Methotrexate on days 1 and day 5 of cycles 2-6 (Arm 4)

Ibrutinib given on day -14 to day -1 on cycle 1 (Arm 1)

Ibrutinib given on days 1-10 for cycles 1-6 (Arm 4)